Renaissance Technologies LLC Acquires 78,900 Shares of Emergent Biosolutions Inc. $EBS

Renaissance Technologies LLC raised its holdings in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 13.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 656,047 shares of the biopharmaceutical company’s stock after buying an additional 78,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Emergent Biosolutions were worth $5,445,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in EBS. Palumbo Wealth Management LLC boosted its position in shares of Emergent Biosolutions by 143.0% during the 4th quarter. Palumbo Wealth Management LLC now owns 117,121 shares of the biopharmaceutical company’s stock valued at $1,448,000 after acquiring an additional 68,925 shares during the last quarter. Ritholtz Wealth Management bought a new position in shares of Emergent Biosolutions in the fourth quarter worth approximately $1,346,000. Evolve Private Wealth LLC bought a new position in shares of Emergent Biosolutions in the first quarter worth approximately $546,000. Wealth Enhancement Advisory Services LLC raised its stake in Emergent Biosolutions by 14.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 1,625 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Emergent Biosolutions by 164.5% in the fourth quarter. SG Americas Securities LLC now owns 40,529 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 25,207 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on EBS shares. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.00.

Emergent Biosolutions Price Performance

Shares of Emergent Biosolutions stock opened at $7.55 on Thursday. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $389.84 million, a PE ratio of -26.98 and a beta of 2.35. The business’s 50-day moving average price is $7.98 and its 200-day moving average price is $8.83. Emergent Biosolutions Inc. has a 12 month low of $6.03 and a 12 month high of $14.06.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. The company had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Insiders Place Their Bets

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by corporate insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.